Colombia vs Mozambique: Average cost of drugs for extensively drug-resistant tuberculosis
Colombia
5,370 constant 2022 US$
in 2024
Mozambique
5,675 constant 2022 US$
in 2024
Colombia rank
8th
Mozambique rank
7th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Colombia
- Mozambique
How they compare
Mozambique currently reports 5,675 constant 2022 US$ against 5,370 constant 2022 US$ in Colombia, a difference of 305 constant 2022 US$.
That makes Mozambique's figure about 1.1 times Colombia's.
Across all 6 years both countries report, Mozambique has been ahead every year.
Colombia ranks 8th and Mozambique ranks 7th of 56 countries.
Mozambique has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Colombia | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,800 constant 2022 US$ | 4,446 constant 2022 US$ | 1,646 constant 2022 US$ | Mozambique |
| 2020s | 1,658 constant 2022 US$ | 4,938 constant 2022 US$ | 3,280 constant 2022 US$ | Mozambique |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Colombia or Mozambique?
- Mozambique, at 5,675 constant 2022 US$ against 5,370 constant 2022 US$ in Colombia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Colombia and Mozambique?
- 305 constant 2022 US$, with Mozambique ahead.
- How many years of comparable data are there for Colombia and Mozambique?
- 6 years are reported by both, from 2019 to 2024.
- How do Colombia and Mozambique rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Colombia ranks 8th and Mozambique ranks 7th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.